ArticleInfection and drug resistance2018
Widespread amphotericin B-resistant strains of
Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Article
- Adaptation Under Pressure: Resistance and Stress Response Interplay in ClinicalJournal of fungi (Basel, Switzerland) · 2025Article
- Molecular Identification ofInfection and drug resistance · 2025Article
- High prevalence of azole resistance among environmentalFrontiers in microbiology · 2025Article
- The proteomic response ofmicroLife · 2025Article
- Isavuconazole and Amphotericin B Synergic Antifungal Activity: In Vitro Evaluation on Pulmonary Aspergillosis Molds Isolates.Antibiotics (Basel, Switzerland) · 2024Article
- Hospital distribution, seasonality, time trends and antifungal susceptibility profiles of all Aspergillus species isolated from clinical samples from 2015 to 2022 in a tertiary care hospital.BMC microbiology · 2024Article
- Surveillance of Amphotericin B and Azole Resistance inJournal of fungi (Basel, Switzerland) · 2023Article
- Alternative Non-Mammalian Animal and Cellular Methods for the Study of Host-Fungal Interactions.Journal of fungi (Basel, Switzerland) · 2023Review
- Work in nursing homes and occupational exposure to endotoxin and bacterial and fungal species.Annals of work exposures and health · 2023Article
- Article
- Plant as an Alternative Source of Antifungals againstPlants (Basel, Switzerland) · 2022Review
- Azole Resistance andJournal of fungi (Basel, Switzerland) · 2022Article
- Genetic validation of Aspergillus fumigatus phosphoglucomutase as a viable therapeutic target in invasive aspergillosis.The Journal of biological chemistry · 2022Article
- Unravelling the Molecular Identification and Antifungal Susceptibility Profiles ofJournal of fungi (Basel, Switzerland) · 2022Article
- Pre-Exposure With Extracellular Vesicles FromFrontiers in cellular and infection microbiology · 2022Article
- Recent Advances in Fungal Infections: From Lung Ecology to Therapeutic Strategies With a Focus onFrontiers in medicine · 2022Review
- In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China.Infection and drug resistance · 2022Article
- Genetic Analyses of Amphotericin B Susceptibility inJournal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAmphotericin B (AMB) is one of the major antifungal drugs used in the management of aspergillosis and is especially recommended for treating triazole-resistant strains of
methodsThe in vitro susceptibilities of 195 environmental and clinical
resultsOf the 195 isolates, 188 (96.4%) had the minimum inhibitory concentration (MIC) of AMB ≥2 mg/L, with approximately 80% and 20% of all clinical and environmental isolates having MICs of ≥ 4 mg/L. Overall, the clinical isolates were less susceptible to AMB than environmental isolates (
conclusionThe widespread AMB resistance suggests that using AMB in the management of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.